Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial?

被引:32
作者
Spicer, Jonathan D.
Stiles, Brendon M.
Sudarshan, Monisha
Correa, Arlene M.
Ferri, Lorenzo E.
Altorki, Nasser K.
Hofstetter, Wayne L.
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Cardiovasc & Thorac Surg, Houston, TX 77030 USA
[2] McGill Univ Hlth Ctr, Div Thorac Surg, Montreal, PQ, Canada
[3] Weill Cornell Med Coll, Dept Cardiothorac Surg, New York, NY USA
关键词
CANCER; TRIAL; CARCINOMA; SURVIVAL; SURGERY; CHEMORADIOTHERAPY;
D O I
10.1016/j.athoracsur.2015.11.070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Preoperative chemotherapy (ChT) or chemoradiation (ChRT) are associated with improved outcomes compared with up-front surgical resection in patients with locally advanced esophageal adenocarcinoma (EAC). Two randomized controlled trials comparing these therapies included nonradical resection and failed to reach significance. We hypothesized that additional regional radiotherapy does not benefit patients undergoing en bloc resection. Methods. We performed a multiinstitutional study using three prospectively entered databases from high-volume esophageal centers. Inclusion criteria were patients with EAC treated with preoperative ChT or ChRT, followed by modified en bloc esophagectomy. To minimize issues of stage migration and heterogeneity, we limited the study to patients with cT3 N1 M0 EAC. Survival was assessed by the Kaplan-Meier method, and step-wise multivariable analyses were used to explore variables independently associated with survival outcomes. Radical resections included two-and three-field lymphadenectomies, dependent solely on surgeon/institutional preference. Results. We identified 214 patients with cT3 N1 disease, of which 114 underwent preoperative ChT vs 100 who underwent ChRT. Median survival was 31.2 months (95% confidence interval, 20.7 to 41.7 months) for the ChT group vs 39.2 months (95% confidence interval, 27.3 to 51.0 months) for the ChRT group (p = 0.665). Mortality at 90 days was 5.3% for ChT vs 4% for ChRT (p = 0.754). No differences were noted between patterns of locoregional and distant recurrence between both groups. There were no significant differences in major postoperative morbidity between both groups. Conclusions. Given a modified en bloc esophagectomy, type of preoperative therapy was not a significant determinant of overall survival or disease-free survival. Although preoperative ChRT did not add perioperative risk, it also did not prolong survival. The role of preoperative radiotherapy in the setting of a planned radical resection should be further evaluated. (C) 2016 by The Society of Thoracic Surgeons
引用
收藏
页码:1262 / 1270
页数:9
相关论文
共 16 条
[1]   Should en bloc esophagectomy be the standard of care for esophageal carcinoma? [J].
Altorki, N ;
Skinner, D .
ANNALS OF SURGERY, 2001, 234 (05) :581-587
[2]   Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial [J].
Burmeister, Bryan H. ;
Thomas, Janine M. ;
Burmeister, Elizabeth A. ;
Walpole, Euan T. ;
Harvey, Jennifer A. ;
Thomson, Damien B. ;
Barbour, Andrew P. ;
Gotley, David C. ;
Smithers, B. Mark .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) :354-360
[3]   Current Status of Management of Malignant Disease: Current Management of Esophageal Cancer [J].
Cools-Lartigue, Jonathan ;
Spicer, Jonathan ;
Ferri, Lorenzo E. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2015, 19 (05) :964-972
[4]   Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer [J].
Dhupar, R. ;
Correa, A. M. ;
Ajani, J. ;
Betancourt, S. ;
Mehran, R. J. ;
Swisher, S. G. ;
Hofstetter, W. L. .
DISEASES OF THE ESOPHAGUS, 2014, 27 (08) :770-776
[5]   Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial [J].
Ferri, L. E. ;
Ades, S. ;
Alcindor, T. ;
Chasen, M. ;
Marcus, V. ;
Hickeson, M. ;
Artho, G. ;
Thirlwell, M. P. .
ANNALS OF ONCOLOGY, 2012, 23 (06) :1512-1517
[6]   Trends in esophageal adenocarcinoma incidence and mortality [J].
Hur, Chin ;
Miller, Melecia ;
Kong, Chung Yin ;
Dowling, Emily C. ;
Nattinger, Kevin J. ;
Dunn, Michelle ;
Feuer, Eric J. .
CANCER, 2013, 119 (06) :1149-1158
[7]   Diagnosis and Staging of Cancer of the Esophagus and Esophagogastric Junction [J].
Li, Zhigang ;
Rice, Thomas W. .
SURGICAL CLINICS OF NORTH AMERICA, 2012, 92 (05) :1105-+
[8]   Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma [J].
Murphy, Caitlin C. ;
Correa, Arlene M. ;
Ajani, Jaffer A. ;
Komaki, Ritsuko U. ;
Welsh, James W. ;
Swisher, Stephen G. ;
Hofstetter, Wayne L. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2013, 17 (08) :1359-1369
[9]   Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus - Five-year survival of a randomized clinical trial [J].
Omloo, Jikke M. T. ;
Lagarde, Sjoerd M. ;
Hulscher, Jan B. F. ;
Reitsma, Johannes B. ;
Fockens, Paul ;
van Dekken, Herman ;
ten Kate, Fiebo J. W. ;
Obertop, Huug ;
Tilanus, Hugo W. ;
van Lanschot, J. Jan B. .
ANNALS OF SURGERY, 2007, 246 (06) :992-1001
[10]   The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence [J].
Pohl, H ;
Welch, HG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (02) :142-146